DB:5TA

Stock Analysis Report

Executive Summary

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies.

Snowflake

Fundamentals

Excellent balance sheet with moderate growth potential.

Share Price & News

How has Aimmune Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.9%

5TA

-0.4%

DE Biotechs

2.4%

DE Market


1 Year Return

-4.6%

5TA

1.8%

DE Biotechs

4.9%

DE Market

Return vs Industry: 5TA underperformed the German Biotechs industry which returned 1.8% over the past year.

Return vs Market: 5TA underperformed the German Market which returned 4.9% over the past year.


Shareholder returns

5TAIndustryMarket
7 Day-0.9%-0.4%2.4%
30 Day11.7%-5.4%2.3%
90 Day37.0%-6.7%2.7%
1 Year-4.6%-4.6%2.0%1.8%8.2%4.9%
3 Year45.7%45.7%67.9%66.1%18.3%8.0%
5 Yearn/a12.0%9.5%44.2%24.6%

Price Volatility Vs. Market

How volatile is Aimmune Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aimmune Therapeutics undervalued compared to its fair value and its price relative to the market?

7.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 5TA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 5TA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 5TA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 5TA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 5TA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 5TA is overvalued based on its PB Ratio (7.9x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Aimmune Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

72.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5TA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 5TA is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: 5TA's loss is forecast to worsen by 0% next year.

Revenue vs Market: Insufficient data to determine if 5TA's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 5TA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 5TA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aimmune Therapeutics performed over the past 5 years?

-49.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 5TA is unprofitable, and losses have increased over the past 5 years at a rate of -49.7% per year.

Accelerating Growth: Unable to compare 5TA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5TA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4%).


Return on Equity

High ROE: 5TA has a negative Return on Equity (-110.18%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: 5TA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 5TA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Aimmune Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 5TA's short term assets ($250.5M) exceeds its short term liabilities ($43.2M)

Long Term Liabilities: 5TA's short term assets (250.5M) exceeds its long term liabilities (50.6M)


Debt to Equity History and Analysis

Debt Level: 5TA's debt to equity ratio (18.8%) is considered satisfactory

Reducing Debt: Insufficient data to determine if 5TA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 5TA has a low level of unsold assets or inventory.

Debt Coverage by Assets: 5TA's debt is covered by short term assets (assets are 6.502900x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 5TA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 5TA has sufficient cash runway for 2.641371 years if free cash flow continues to reduce at historical rates of -43.1% each year.


Next Steps

Dividend

What is Aimmune Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 5TA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 5TA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 5TA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5TA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5TA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Aimmune Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.5yrs

Average management tenure


CEO

Jayson Donald Dallas (51yo)

1.3yrs

Tenure

US$9,481,733

Compensation

Dr. Jayson Donald Alexander Dallas, M.D. has been President, Chief Executive Officer and Director of Aimmune Therapeutics, Inc. since June 19, 2018. He served as the Chief Commercial Officer and Executive  ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jayson Donald's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Insufficient data to compare Jayson Donald's compensation with company performance.


Management Age and Tenure

3.5yrs

Average Tenure

53yo

Average Age

Experienced Management: 5TA's management team is considered experienced (3.5 years average tenure).


Board Age and Tenure

3.6yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 5TA's board of directors are considered experienced (3.6 years average tenure).


Insider Trading

Insider Buying: 5TA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$31,61520 Sep 19
Eric Bjerkholt
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,550
Max PriceUS$20.40
BuyUS$87,82220 Nov 18
Jayson Donald Dallas
EntityIndividual
Role
Chief Executive Officer
President
Shares3,650
Max PriceUS$24.06

Ownership Breakdown


Management Team

  • Stephen Dilly (59yo)

    Special Advisor

    • Tenure: 1.3yrs
    • Compensation: US$2.05m
  • Eric Bjerkholt (59yo)

    Chief Financial Officer

    • Tenure: 2.5yrs
    • Compensation: US$2.11m
  • Dan Adelman (62yo)

    Chief Medical Officer

    • Tenure: 3.3yrs
    • Compensation: US$2.13m
  • Jeff Knapp (53yo)

    Chief Operating Officer

    • Tenure: 3.7yrs
    • Compensation: US$1.73m
  • Laura Hansen

    Vice President of Investor Relations

    • Tenure: 3.6yrs
  • Doug Sheehy (52yo)

    General Counsel & Secretary

    • Tenure: 3.5yrs
    • Compensation: US$3.25m
  • William Turner

    Senior Vice President of Global Regulatory Affairs & Quality Assurance

    • Tenure: 3.7yrs
  • Mary Rozenman (38yo)

    Senior Vice President of Corporate & Strategy Development

    • Tenure: 3.7yrs
    • Compensation: US$1.06m
  • Alison Marquiss

    Vice President of Community and Public Affairs

    • Tenure: 0yrs
  • Jayson Donald Dallas (51yo)

    President

    • Tenure: 1.3yrs
    • Compensation: US$9.48m

Board Members

  • Kate Falberg (58yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$334.48k
  • Mark McDade (64yo)

    Chairman

    • Tenure: 4.4yrs
    • Compensation: US$353.09k
  • Patrick Enright (58yo)

    Director

    • Tenure: 6.5yrs
    • Compensation: US$324.48k
  • Thomas Casale

    Member of Scientific Advisory Board

    • Tenure: 2.8yrs
  • Mark Iwicki (53yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$318.48k
  • Stacey Seltzer (42yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$321.87k
  • A. Burks

    Member of Scientific Advisory Board

    • Tenure: 2.8yrs
  • Jayson Donald Dallas (51yo)

    President

    • Tenure: 1.3yrs
    • Compensation: US$9.48m
  • Kirsten Beyer

    Member of Scientific Advisory Board

    • Tenure: 2.8yrs
  • Jonathan Hourihane

    Member of Scientific Advisory Board

    • Tenure: 2.8yrs

Company Information

Aimmune Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aimmune Therapeutics, Inc.
  • Ticker: 5TA
  • Exchange: DB
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.576b
  • Listing Market Cap: US$1.415b
  • Shares outstanding: 62.67m
  • Website: https://www.aimmune.com

Number of Employees


Location

  • Aimmune Therapeutics, Inc.
  • 8000 Marina Boulevard
  • Suite 300
  • Brisbane
  • California
  • 94005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AIMTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2015
5TADB (Deutsche Boerse AG)YesCommon StockDEEURAug 2015
0HBBLSE (London Stock Exchange)YesCommon StockGBUSDAug 2015

Biography

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Dese ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 21:48
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.